Serum Magnesium Level in Patients With Chronic Renal Failure

1Dr. Nitin N. Jadhav, 2Dr. Hardik Mahendra Kumar Patel

Department of Medicine, Krishna Institute of Medical Sciences, Karad-415110, Maharashtra

Correspondence:
Dr. Nitin N. Jadhav
Department of Medicine, Krishna Institute of Medical Sciences, Karad-415110, Maharashtra
Email Id: Jadhavnitin7801@gmail.com

INTRODUCTION

Chronic kidney disease (CKD) is an overall medical issue, influencing a huge number of people.¹ The issue is ineffectively depicted by the quantity of individuals that will start renal substitution treatment, as the frequency of 1-3 for every 10,000 every year in everybody may appear small.²,³ However, interminable dialysis treatment and transplantation enormously affect the life of individual patients and their families, renal replacement treatment is very expensive.⁴

Magnesium (Mg ++ ) is the fourth most abundant and second most important intracellular extract in the body. In patients with CKD and end stage renal disease (ESRD), Mg ++ homeostasis may change. An understanding of physiology in Mg ++ handling is relevant to those who have a relationship with CKD and ESRD patients.⁵

Hence, the present study was done to assess serum magnesium levels in patients with CKD and to detect a correlation of serum magnesium with clinical features and severity of impairment of renal function.

AIM AND OBJECTIVES

Aim of the Study
To detect correlation of serum magnesium with clinical features and severity of renal impairment

Objectives of the Study
To assess the levels of serum magnesium in chronic kidney disease patients. To find effect of Hemodialysis on serum magnesium level. To find whether serum magnesium can be used as a marker to predict morbidity in chronic kidney disease.

REVIEW OF LITERATURE

Clinical and epidemiological reports provided a relationship between numerous factors and the initiation, progression of CKD. These are grouped into two well defined classes.

1. Risk factors: those that cause the CKD.
2. Risk markers: those are associated with CKD in absence of established causal relations.

Progressive glomerulopathies are among kidney diseases which cause rapid permanent loss of renal function. Most kidney diseases progress slowly over ten to fifteen years, initially without symptoms. This makes very difficult to identify the etiology. Indications are that environmental and lifestyle factors affect kidney function even though genetic factors also show some relevance.⁶ Generally, kidney function reduces with age even among healthy subjects; this reduction or decline however is not similar but exhibits considerable individual variation.⁷

All kidney diseases progress to terminal renal failure relatively independent of the initial disease. Diabetic nephropathy, chronic glomerular diseases and hypertensive nephrosclerosis are among the most widespread causes of CKD.⁸ A primary disease eventually leads to secondary glomerular injury and nephron loss that is clinically characterized by proteinuria and hypertension, which leads to inflammation and/or scarring which causes kidney failure.
and ultimately a gradual elevation in the plasma creatinine concentration and a progressive decline in GFR.\textsuperscript{9} Apparently, the excessive protein filtration, which is caused by the glomerular hypertension, might per se have toxic effects on the kidneys and increase the rate of progression.\textsuperscript{10,11} Studies in rats, have suggested that hyperfiltration and glomerular hypertension may play important roles.\textsuperscript{12} Hyperfiltration is observed in diabetes and obesity, but also in any condition associated with a reduced number of nephrons.\textsuperscript{13} To compensate for this nephron loss, the glomerular plasma flow rate and glomerular hydrostatic pressure increase in the surviving nephrons, thus raising the single nephron glomerular filtration rate. Initially, these changes are adaptive because they maintain the overall GFR. The central mediator of this observed glomerular haemodynamic changes seems to be angiotensin II, but it also controls other factors that might be of importance in the progression of kidney disease, such as the production of reactive oxygen species, the regulation of cytokines and profibrotic growth factors among others. Inappropriate activation of the other systems such as the sympathetic system, the endothelin system and of aldosterone has also been implicated in the progression of CKD.\textsuperscript{14}

\textbf{HYPERTENSION}

There is compelling evidence from the epidemiological studies that hypertension causes a decline in renal function\textsuperscript{15,16,17} and increases risks of ESKD.\textsuperscript{18,19} However, some investigators have questioned whether non- malignant hypertension (in contrast to malignant hypertension) is an important initiator of kidney disease.\textsuperscript{20,21} Although evidence that hypertension accelerates the progression of already existing renal failure is overwhelming, there is lack of data from clinical trials that aggressive treatment of hypertension reduces risk of kidney disease onset.

\textbf{DIABETES}

Diabetes contributes substantially to the burden of ESKD\textsuperscript{22,23} thus the rapidly rising trend in type 2 diabetes prevalence throughout the world is of major concern.\textsuperscript{24} There are indications that genetic susceptibility to nephropathy development may be in both type 1 and type 2 diabetes, although gene hunting studies have been unable to identify any particular mutations which could explain why diabetic nephropathy is mostly associated with diabetic patients.\textsuperscript{25} Changing environmental or behavioural factors appear to be of importance for the development of diabetic nephropathy beside the genetic factors. Among Pima Indians where both type 2 diabetes and diabetic nephropathy are highly prevalent, the incidence rate of proteinuria among type 2 diabetics has doubled during the last four decades, notwithstanding improvements in plasma glucose levels and blood pressure.\textsuperscript{26}

\textbf{TOBACCO}

Tobacco belongs to the Nicotiana species. It has been used by indigenous Americans for medicinal and ceremonial purposes for many years. Early in the 20th century the habit of using tobacco as a stimulant became widespread.\textsuperscript{27} Tobacco smoking is the most identifiable cause of adult death in the developed countries, with the exception of hypertension. In recent decades a growing body of literature has emerged, supporting the idea that smoking is associated with adverse effects on the kidneys. Evidence suggests that smoking has a effect on kidneys in diabetics and in individuals with hypertension and pre-existing renal disease. Smoking may also cause renal damage in healthy individuals, which is independent of other factors according to experimental studies and population based epidemiological studies. Smoking in diabetes has been linked to increased risks of microalbuminuria development, accelerated progression from microalbuminuria to proteinuria and accelerated progression of manifest renal failure.\textsuperscript{28}

\textbf{PROTEIN INTAKE}

A more than sixty years ago it was suggested that low protein diet (LPD) could preserve renal function in a patient with CKD.\textsuperscript{29} A is hypothesized that a LPD would reduce the workload of surviving nephrons in diseased kidneys and thus minimizes further loss of renal function. Brenner et al (1982) extended this view and postulated the hyperfiltration theory. Based on animal studies, he suggested that sustained excess of dietary protein cause increases in renal blood flow and glomerular filtration rate that lead to intrarenal hypertension, ultimately resulting in progressive sclerosis and deterioration of renal function. Whether or not an excessive protein intake can be detrimental in subjects without kidney disease has not been thoroughly evaluated.\textsuperscript{30}

\textbf{OBESITY}

Obesity, a component of the metabolic syndrome, has become a key worldwide problem. Although this phenomenon may result from altered dietary patterns and a sedentary lifestyle among people in developed countries, which is rapidly emerging problem in developing countries. Worldwide obesity has increased 3-fold since 1980 and according to reports from the World Health Organization (W.H.O.), over one billion adults are overweight (body mass index [BMI] ≥25 kg/m\textsuperscript{2}) with at least 300 million being obese (BMI ≥ 30 kg/m\textsuperscript{2}).\textsuperscript{31} There are further, great concerns about the rising prevalence of overweight and obesity among adolescents and children of school going age. Obesity contributes significantly to the burden of diseases such as cardiovascular disease, cancers, type 2 diabetes and hypertension among others.\textsuperscript{32}

\textbf{ANALGESICS}

A more than fifty years ago,\textsuperscript{33} observed an association between chronic interstitial nephritis and excessive consumption of combination analgesics containing phenacetin. Soon thereafter reports of an increased occurrence of renal papillary necrosis among heavy users of phenacetin started appearing.\textsuperscript{34} This nephropathy associated with analgesic use was initially called phenacetin nephropathy. It was later renamed analgesic associated nephropathy (AAN) since a lot of analgesics came under suspicion of causing nephropathy. During the last two decades results from epidemiological studies suggested that
analgesics do not only cause classical AAN but may also increase the risk of CKD and ESKD in general. Moreover, there are indications that analgesic use may exacerbate pre-existing CKD. The mechanisms involved in analgesic induced renal injury remains unclear but cell injury, free radical formation, prostaglandin inhibition, reduced medullary blood flow and possibly an immunological mechanism are suggested modes of actions. Prostaglandin inhibition by aspirin and other NSAIDs causes redistribution of renal blood flow from renal medulla to renal cortex potentially resulting in the medullary ischaemia and eventual necrosis of renal papillae.

**DYSLIPIDAEMIA**

Renal disease, in early as well as well as advanced stages, associated with abnormalities in lipoprotein metabolism. Dyslipidaemia appears to be independently associated with increased progression rate of CKD in patients with kidney disease, and with increased risk of graft loss after renal transplantation. Moreover, there are indications that dyslipidaemia might initiate kidney disease. Two cohort studies in the general population reported links between elevated plasma triglycerides, high total serum cholesterol, and low high density lipoprotein cholesterol on the one hand and increases in serum creatinine at follow up on the other.

**GENETIC SUSCEPTIBILITY**

There are indications that a generalized genetic susceptibility contributes to the development of ESKD. The observation that there is a clear familial aggregation of ESKD due to diabetes, hypertension and glomerulonephritis, initiated the search for specific “candidate genes” that might be involved in renal diseases. Some specific mutations are suggested to increase the susceptibility for glomerular damage, and are implicated in the aetiology of focal segmental nephrosclerosis. Studies using genome scan approach, which has the potential for a more comprehensive evaluation of inheritance throughout the genome and to locate previously unknown genes related to diseases, recently found evidence of susceptibility loci for diabetic nephropathy.

**MATERIAL AND METHODS**

The present study was a descriptive cross-sectional non-traditional observational study conducted at a tertiary institution to assess serum magnesium levels in patients with chronic kidney disease. A minimum sample size of approximately 80 cases during study period was randomly selected and included in present study. The study was performed between October 2016 and March 2018. The study was done in the ICU of Ward and Department of Medicine, Krishna Hospital and Medical Research Center, Karad.

**OBSERVATION AND RESULTS**

**Table 1: Distribution according to gender**

| Gender | n=80 | %   |
|--------|------|-----|
| Male   | 47   | 58.75 |
| Female | 33   | 41.25 |

Distribution of patients with gender shows predominance of males (58.75%) while females were 41.25%. There was significant statistical difference of gender. (chi square: 4.9; DF: 1; p= 0.027). (Table 1)

**Table 2: Distribution according to stage of CKD**

| Stages of CKD | n=80 | %   |
|---------------|------|-----|
| 3             | 02   | 02.50 |
| 4             | 10   | 12.50 |
| 5             | 68   | 85.00 |

Frequency of patients in different stage of CKD showed predominance of patients in stage 5 (85%) followed by stage 4 (12.50%). The stage 3 was observed in only 2.50% patients. There was no patient with stage 1 and 2 CKD observed in present study. It was significant statistical difference of patients with stage of CKD. (DF: 2; p<0.0001). (Table 2)

**Table 3: Anthropometric characteristics**

| Anthropometry | Mean ±SD |
|---------------|----------|
| Weight (kg)   | 54.62 ±12.42 |
| Height (cms)  | 157.97 ±06.67 |
| BMI (kg/m²)   | 22.21 ±05.12 |

Anthropometric distribution of patients shows the mean weight of patients was 54.62 (±12.42) kg. The mean height of patients in present study was 157.97 (±06.67) cms while mean BMI of the patients was 22.21 (±05.12) kg/m2. (Table 3)

**Table 4: Laboratory parameters in study population**

| Investigations | Mean ±SD |
|---------------|----------|
| Hemoglobin (g/dl) | 11.63 ±1.90 |
The mean hemoglobin of patients was 11.63 (±1.90). The mean blood urea of patients was 111.69 (±16.59) while mean serum creatinine among patients was 7.78 (±2.98). The mean serum magnesium was 4.34 (±1.38) while serum sodium, serum calcium, serum potassium and serum phosphorus was 141.81 (±4.62), 9.50 (±0.61), 4.43 (±0.38) and 5.42 (±0.87) respectively. (Table 4)

Table 5: Distribution of Serum Magnesium according to stage of CKD

| Stage of CKD | n=80 | Serum Magnesium (mg/dl) |
|--------------|------|-------------------------|
| 3            | 02   | 1.15 ± 0.07             |
| 4            | 10   | 3.42 ± 0.52             |
| 5            | 68   | 4.71 ± 1.12             |

Serum magnesium levels in different stage of CKD shows the mean serum magnesium level increases with progression of CKD. This was in stage 3, 4 and 5 CKD was 1.15 (±0.07), 3.42 (±0.52) and 4.71 (±1.12) respectively. (Table 5)

In present study majority patients (55) were not on dialysis on admission and 25 patients were on dialysis (old patients). Among 55 patients who were not on dialysis (newly diagnosed) total 44 patient required dialysis hence total 69 patients were on dialysis in present study. (Table 6)

Table 6: Distribution of patients according to dialysis

| Dialysis | n=80 | New (n=55) | Old (n=25) | %  |
|----------|------|------------|------------|----|
| Present  | 44   | 25         | 86.25      |
| Absent   | 11   | 00         | 13.75      |

In present study majority patients (55) were not on dialysis on admission and 25 patients were on dialysis (old patients). Among 55 patients who were not on dialysis (newly diagnosed) total 44 patient required dialysis hence total 69 patients were on dialysis in present study. (Table 6)

DISCUSSION

Magnesium is now gaining critical status for electrolyte and metabolic disturbances as other electrolytes have been studied extensively.

The current cross-sectional study was performed to assess serum magnesium levels in cases with CKD and to detect the correlation of serum magnesium with clinical features and severity of renal impairment.

The serum magnesium among patients showed that majority of patients presented with hyper magnesium (61.25%) followed by normal magnesium levels (37.50%). The hypomagnesemia level was observed only in one patient. In a study by Ahmed H. Mitwalli et al on serum magnesium levels in CRF patients observed 10 patients (8.7%) had Mg levels of <0.7 mmol/L, 13 (11.3%) had between 0.7 to 1.1 mmol/L while 26 (23.9%) showed levels of >1.1 mmol/L.113.

The mean serum magnesium value was high [5.28 (±0.44)] in patients with encephalopathy than in those without.114 In present study the mean serum magnesium value was high in patients with vomiting and nausea which was 4.96 (±0.95) and 4.71 (±1.16) while mean serum magnesium value was in patients without oliguria and oedema which was 4.82 (±0.98) and 4.71 (±1.04). In present study it was observed, there was bradycardia in a patients with high serum magnesium levels with statistically significant correlation (p=0.0120) which is similar in study done by Sharma SK et al.41

The mean serum magnesium was 4.89 (±1.05), 3.84 (±1.47) and 3.24 (±1.45) in patients with heart rate <60, 60-100 and >100 respectively. The correlation of serum magnesium and dialysis among patients showed that serum magnesium before dialysis was more (4.66 ±1.61) compared to after dialysis (2.84 ±0.92) with statistically significant value (p < 0.001).

CONCLUSION

The serum magnesium among patients with CKD had hyper magnesium. The serum magnesium level rises as kidney function deteriorates. There is significant fall in serum magnesium level after dialysis. There is significant high level of serum magnesium in patients with encephalopathy and patients with bradycardia. All patients suffering from CKD should be advised low magnesium in diet similar restriction to potassium to prevent CNS depression & cardiac arrhythmia. Serum magnesium should be measured regularly in patients with CKD and adjust dialysate
magnesium accordingly to maintain plasma magnesium within normal range. Serum magnesium is a worthwhile tool for assessing duration of disease and morbidity in patients with CKD. Its estimation helps in evaluating conservative treatment and dialysis in CKD. Hence early evaluation and treatment of underlying cause for CKD is necessary to prevent further complication and kidney damage.

**BIBLIOGRAPHY**

1. Di Angelantonio E., Danesh J., Eiriksdottir G. and Gudnason V. Renal function and risk of coronary heart disease in general populations new prospective study and systematic review. PLoS Med 2007; 4: e270.
2. Lysaght M.J. Maintenance dialysis population dynamics current trends and long-term implications. J Am Soc Nephrol 2002; 13: S37-40.
3. Hallan S.I., Coresh J., Astor B.C., Asberg A., Powe N.R., Romundstad S., Hallan H.A., Lydersen S. and Holmen J. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284.
4. Dor A., Pauly M.V., Eichleay M.A. and Held P.J. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ 2007; 7: 73-111.
5. Cunningham J., Rodriguez M., Messa P. Magnesium in chronic kidney disease stages 3 and 4 and in dialysis patients. Clin Kidney J 2012; 5: 139-151.
6. Bowden D.W. Genetics of kidney disease. Kidney Int Suppl 2003; S8-12.
7. Lindeman R.D., Tobin J. and Shoch N.W. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285.
8. Remuzzi G., Ruggenenti P. and Bonini A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2-15.
9. Jacobson H.R. Chronic renal failure: pathophysiology. Lancet 1991; 338: 419-423.
10. Remuzzi G. and Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456.
11. Tryggvason K. and Pettersson E. Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Intern Med 2003; 254: 216-224.
12. Brenner B.M., Meyer T.W. and Hosterter T.H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982; 307: 652-659.
13. Brenner B.M., Lawler E.V. and Mackenzie H.S. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49: 1774-1777.
14. Gross M.L. and Amann K. Progression of renal disease: new insights into risk factors and pathomechanisms. Curr Opin Nephrol Hypertens 2004; 13: 307-312.
15. Ishida K., Ishida H., Narita M., Sairenchi T., Saito Y., Fukutomi H., Takahashi H., Yamagata K. and Koyama A. Factors affecting renal function in 119 985 adults over three years. QJM 2001; 94: 541-550.
16. Young J.H., Klag M.J., Muntner P., Whyte J.L., Pahor M. and Coresh J. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 2002; 13: 2776-2782.
17. Fox C.S., Larson M.G., Leip E.P., Culleton B., Wilson P.W. and Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850.
18. Perry H.M., Jr., Miller J.P., Forenoff J.R., Baty J.D., Sambhi M.P., Rutan G., Moskowitz D.W. and Carmody S.E. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25: 587-594.
19. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Ford C.E., Shulman N.B. and Staimier J. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18.
20. Hsu C.Y., M Culloch C.E. and Curhan G.C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13: 504-510.
21. Kincaid-Smith P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'. J Hypertens 2004; 22: 1051-1055.
22. Brancati F.L., Whelton P.K., Randall B.L., Neaton J.D., Staimier J. and Klag M.J. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997; 278: 2069-2074.
23. Ritz E., Rychlik I., Locatelli F. and Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808.
24. Zimmert P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab 2003; 29: 59-18.
25. Bergren H. and Levestad T. Diabetic nephropathy and end-stage renal failure the Norwegian story. Adv Ren Replace Ther 2001; 8: 4-12.
26. Nelson R.G., Morgenstern H. and Bennett P.H. An epidemic of proteinuria in Pima Indians with type 2 diabetes mellitus. Kidney Int 1998; 54: 2081-2088.
27. Routh H.B., Bhowmik K.R., Parish J.L. and Parish L.C. Historical aspects of tobacco use and smoking. Clin Dermatol 1998; 16: 539-544.
28. Orth S.R. Effects of smoking on systemic and intrarenal hemodynamics influence on renal function. J Am Soc Nephrol 2004;15 (Suppl 1):S58-63.
29. Addis T. Glomerular nephritis: diagnoses and treatment. New York MacM Milam; 1948.
30. WHO. Obesity: Preventing and Managing the Global
Serum Magnesium Levels in Patients with Chronic Renal Failure

Epidemic. Geneva. WHO; 1998.
31. O'Brien P.E. and Dixon J.B. The extent of the problem of obesity. Am J Surg 2002; 184: 4S-8S.
32. Spuhler O. and Zollinger H.U. Chronic interstitial nephritis. Z Klin Med 1953; 151: 1-50.
33. Burry A.F. A profile of renal disease in Queensland results of an autopsy survey. Med J Aust 1966; 1: 826-834.
34. Duggin G.G. Combination analgesic-induced kidney disease the Australian experience. Am J Kidney Dis 1996; 28: 539-47.
35. Sabatini S. Pathophysiologic mechanisms in analgesic-induced papillary necrosis. Am J Kidney Dis 1996; 28: 534-38.
36. Samuelsson O., Mulec H., Knight-Gibson C., Attman P.O., Kron B., Larsson R., Weiss L., Wedel H. and Alaupovic P. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908-1915.
37. Muntner P., Coresh J., Smith J.C., Eckfeldt J. and Klagger M.J. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301.
38. Freedman B.J. Susceptibility genes for hypertension and renal failure. J Am Soc Nephrol 2003; 14: S192-194.
39. Winn M.P. Approach to the evaluation of heritable diseases and update on familial focal segmental glomerulosclerosis. Nephrol Dial Transplant 2003; 18 (Suppl 6): 14-20.
40. Bowden D.W., Colicigno C.J., Langefeld C.D., Sale M.M., Williams A., Anderson P.J., Rich S.S. and Freedman B.J. A genome scans for diabetic nephropathy in African Americans. Kidney Int 2004; 66: 1517-1526.
41. Sharma SK, Singh R, Patney NL, Singh JB, Sharma AP. Serum magnesium levels in chronic renal failure. Clinical significance and correlation with sodium potassium and calcium. J Assoc Physicians India. 1990 Aug; 38(8): 569-71.

Cite this article: Nitin N. Jadhav et al. 2020. Serum Magnesium Levels in Patients with Chronic Renal Failure. European Journal of Molecular & Clinical Medicine, 7(1), pp. 80 – 85, DOI: https://doi.org/10.5334/ejmcm.283